Also, it is known that the HR factor ATRX is defective in a variety of tumors that are commonly using the alternative lengthening of telomeres (ALT) mechanism of telomere maintenance (representing around 10–15% of all cancers; Dilley and Greenberg, 2015). This evidence concerns the gene ATRX and cancer.